Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 16/20 | 0.59 |
| ▸ | DRD2 | P14416 | 15/20 | 0.59 |
| ▸ | HTR2A | P28223 | 12/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490598 | 1.00 | DRD3 (0.59) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL4481061 | 0.92 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL13630299 | 0.92 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL4494169 | 0.89 | DRD3 (0.52) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL13630532 | 0.89 | DRD3 (0.52) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL4483110 | 0.89 | DRD3 (0.59) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL13630433 | 0.89 | DRD3 (0.59) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL13630053 | 0.89 | DRD2 (0.67) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL4487135 | 0.87 | DRD2 (0.69) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL13629953 | 0.87 | DRD2 (0.69) | DRD3DRD2HTR2AHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD3 1/4885DRD2 4/4885HTR2A 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.